StockNews.AI
KROS
StockNews.AI
206 days

KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the Firm

1. Bragar Eagel & Squire investigates potential claims against Keros. 2. Claims relate to violations of federal securities laws. 3. Keros halted dosing in TROPOS trial due to adverse safety events. 4. Keros's stock fell sharply after the December 12 announcement. 5. Investors are urged to contact the law firm for participation.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Legal investigations and halted trials typically lead to stock price declines. Previous cases show stocks suffer during such scrutiny.

How important is it?

The ongoing investigation and trial issues could directly impact stockholder confidence. Legal actions often lead to significant market reactions.

Why Short Term?

Immediate legal concerns will likely affect Keros's stock price soon. Past examples show rapid price adjustments in similar situations.

Related Companies

KROS
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQ:KROS) on behalf of Keros stockholders. Our investigation concerns whether Keros has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On December 12, 2024, Keros issued a press release "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial." On this news, Keros's stock price fell sharply during intraday trading on December 12, 2024. If you purchased or otherwise acquired Keros shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News